Adenoid cystic carcinoma
MONDO:0004971A malignant tumor arising from the epithelial cells. Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma). Adenoid cystic carcinomas mostly occur in the salivary glands. Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs. Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur. Lymph node metastases are unusual; hematogenous tumor spread is characteristic.
Also known as: adenocystic carcinoma, adenoid cystic cancer, adenoid cystic carcinoma, cylindroid adenocarcinoma, cribriform carcinoma, cylindroma
2792 clinical trials for this condition and its sub-types, 47 tagged with Adenoid cystic carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Adenoid cystic carcinoma
-
2 sub-types
-
2 sub-types
-
Adenoid cystic breast carcinoma 0 trials
-
Cervical adenoid cystic carcinoma 0 trials
-
Cutaneous adenocystic carcinoma 0 trials
-
Esophageal adenoid cystic carcinoma 0 trials
-
Laryngeal adenoid cystic carcinoma 0 trials
-
Lung adenoid cystic carcinoma 0 trials
-
Lymph node adenoid cystic carcinoma 0 trials
-
Pharyngeal adenoid cystic carcinoma 0 trials
-
Prostate adenoid cystic carcinoma 0 trials
-
Tracheal adenoid cystic carcinoma 0 trials
-
Vaginal adenoid cystic carcinoma 0 trials
Most studied deeper sub-types
-
Old drugs, new hope: imatinib combo tested for rare tumors
Disease control CompletedThis early-phase trial tested two cancer drugs—imatinib mesylate and cyclophosphamide—given daily by mouth to 26 people with rare, advanced tumors that had no standard treatment. The main goal was to find the safest dose of imatinib when combined with a fixed dose of cyclophospha…
Phase 1 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Immune cell combo shows promise in tough head and neck cancers
Disease control CompletedThis early-phase trial tested a new approach for people with advanced head and neck cancer that has come back or spread. It combined specially trained natural killer (NK) immune cells with drugs that help the immune system attack cancer. The study enrolled 11 participants to chec…
Phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Experimental drug targets Notch-Activated cancer before surgery
Disease control CompletedThis phase 1 trial tested the drug AL101 in 13 people with a rare salivary gland cancer called adenoid cystic carcinoma that has a specific genetic change (notch activation). Participants received AL101 before their standard surgery to see if it is safe and might help control the…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Immunotherapy combo shows promise for rare salivary cancer
Disease control CompletedThis study tested two immunotherapy drugs, nivolumab and ipilimumab, in 64 people with recurrent or metastatic salivary gland cancer that could not be removed by surgery or treated with radiation. The goal was to see how well the combination shrank tumors and what side effects oc…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Cancer drug shows promise for rare salivary gland tumor
Disease control CompletedThis phase II trial tested the oral drug regorafenib in 38 patients with progressive, recurrent, or metastatic adenoid cystic carcinoma, a rare cancer of the salivary glands. Regorafenib works by blocking signals that help cancer cells grow and by cutting off blood supply to tumo…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 15:32 UTC
-
New scan could help track rare Cancer's response to treatment
Diagnosis CompletedThis pilot study tested whether a special PET/CT scan using a radioactive tracer called Ga-68 PSMA-11 can detect treatment response in patients with metastatic adenoid cystic carcinoma, a rare salivary gland cancer. Six adults with this cancer underwent the scan at two time point…
Phase 2 • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 26, 2026 15:54 UTC